[팜뉴스=김태일 기자] Creo SG announced on the 9th that it will accelerate the commercialization of the world’s first AIDS vaccine “SAV001” by developing a combination delivery vaccine based on the recently launched universal vaccine development platform “SUV-MAP” by its subsidiary Immunovax Bio.
Combination therapy is mainly used in the process of developing anticancer drugs. Biologics companies developing anticancer drugs conduct clinical trials by co-administering them with marketed anticancer drugs to maximize anti-tumor effects and minimize side effects while increasing patient response rates.
Immunovax Bio expects to maximize the AIDS prevention effect of SAV001 through a combined administration strategy. Using SUV-MAP with VSV vector technology, vaccine candidates can be confirmed within 5 months. The company explains that after initially inducing an immune response by administering SAV001, the immune response can be significantly expanded with the VSV vector vaccine.
SAV001, which is about to undergo phase 2 clinical trials in the United States, is a “complete AIDS vaccine” that uses the entire human immunodeficiency virus (HIV) as the antigen. SAV001 is characterized by maximizing the AIDS prevention effect by using the entire virus and maintaining immunity even against mutations. In Phase 1 clinical trials conducted in the United States, antibodies were formed and maintained over a long period of time, and neutralizing antibody responses to various mutant viruses were also confirmed.
A company official said: “We chose this combined delivery strategy to increase the likelihood of success in the phase 2 clinical trial of SAV001. We plan to prepare for the Phase 2 clinical trial in the United States by simultaneously producing samples of SAV001 and developing a drug. vaccine for combined administration”.
He continued: “The combined delivery method is expected to not only maximize the immune response of the AIDS vaccine but also minimize side effects,” and added: “We will accelerate the commercialization of the world’s first AIDS vaccine by conducting research and development in a differentiated way”.
#Creo #worlds #AIDS #vaccine #Advances #coadministration #therapy #maximizing #efficacy
